Juno Therapeutics (JUNO) and Dyax (DYAX) Head to Head Survey
Juno Therapeutics and Dyax are both companies, but which is the better business? We will compare the two companies based on the strength of their earnings, valuation, risk, institutional ownership, dividends, profitability and analyst recommendations. Juno Therapeutics currently has a consensus target price of $56.21, indicating a potential downside of 35.36%.
Start the conversation, or Read more at Daily Political.
Add your comments below
|Dyax gets FDA approval to market Kalbitor for h... (Dec '09)||Dec '09||J van Delft||1|
Find what you want!
Search Dyax Forum Now
Copyright © 2018 Topix LLC